Key result
Plasma ANGPTL4 levels are elevated in patients with Alzheimer's disease compared to healthy controls, and are significantly higher in obese AD patients relative to non-obese AD patients.
Why the study?
Metabolic disorders such as obesity are implicated in Alzheimer's disease development, but the mechanisms behind microglial lipid accumulation remain uncertain.
Observational
ANGPTL4-mediated microglial aging and lipid accumulation may serve as a crucial mechanistic link between Alzheimer's disease and obesity.
Answers are grounded in this paper and cite their sources.
ANGPTL4 may mediate obesity-driven microglial lipid buildup in AD; leaves open causal confirmation and therapeutic targeting.
Increasing evidence suggests that metabolic disorders such as obesity are implicated in the development of Alzheimer's disease (AD). The pathological buildup of lipids in microglia is regarded as a key indicator in brain aging and the progression of AD, yet the mechanisms behind this process remain uncertain. The adipokine ANGPTL4 is strongly associated with obesity and is thought to play a role in the advancement of neurodegenerative diseases. This study utilized RNA sequencing to identify differential expression in lipid-accumulating BV2 microglia and investigated the potential mechanism through ANGPTL4 overexpression in BV2. Subsequently, animal models and clinical data were employed to further explore alterations in circulating ANGPTL4 levels in AD. RNA sequencing results indicated a correlation between ANGPTL4 and microglial lipid accumulation. The overexpression of ANGPTL4 in microglia resulted in increased secretion of inflammatory factors, elevated oxidative stress levels, and diminished antiviral capacity. Furthermore, when simulating the coexistence of AD and obesity through combined treatment with Amyloid-Beta 1–42 peptide (Aβ) and Free Fatty Acids (FFA) in vitro, we observed a notable upregulation of ANGPTL4 expression, highlighting its potential role in the interplay between AD and obesity. In vivo experiments, we also observed a significant increase in ANGPTL4 expression in the hippocampus and plasma of APP/PS1 mice compared to wild-type controls. This was accompanied by heightened microglial activation and reduced expression of longevity-related genes in the hippocampus. Clinical data from the UK Biobank indicated that plasma ANGPTL4 levels are elevated in patients with AD when compared to healthy controls. Moreover, significantly higher ANGPTL4 levels were observed in obese AD patients relative to their non-obese counterparts. Our findings suggest that ANGPTL4-mediated microglial aging may serve as a crucial link between AD and obesity, proposing ANGPTL4 as a potential biomarker for AD. • Microglial lipid droplet accumulation may serve as a key link between Alzheimer's disease (AD) and obesity. • ANGPTL4 impairs microglial antiviral capacity and promotes oxidative stress and inflammatory factor release. • There was an upregulation in ANGPTL4 expression in the hippocampus and plasma of APP/PS1 mice compared to wild-type controls. • ANGPTL4 levels are significantly higher in obese AD patients compared to non-obese AD patients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) conducted an observational in Alzheimer's disease and obesity. ANGPTL4 levels vs. Healthy controls and non-obese AD patients was evaluated on Plasma ANGPTL4 levels. Plasma ANGPTL4 levels are elevated in patients with Alzheimer's disease compared to healthy controls, and are significantly higher in obese AD patients relative to non-obese AD patients.
Synapse has enriched 10 related papers. Consider them for comparative context: